Shari Lynn Caplan

USPTO Granted Patents = 13 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 5.7

ph-index = 5

Forward Citations = 149(Granted Patents)

Location History:

Sloatsburg, NY (US) (2003)
Lunenberg, MA (US) (2018)
Lunenburg, MA (US) (2015 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2003-2024

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11944664 - Fibroblast growth factor-21-Fc fusion proteins (2024-04-02),

2. 11802152 - Methods of treating FGF21-associated disorders (2023-10-31),

3. 11377656 - Chemically modified messenger RNA's (2022-07-05),

4. 11236159 - Methods of treating FGF21-associated disorders (2022-02-01),

5. 11129874 - Nucleic acids encoding FGF21-Fc fusion proteins (2021-09-28),

6. 10669323 - Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins (2020-06-02),

7. 10076554 - FGF21-FC fusion proteins for treating metabolic disorders (2018-09-18),

8. 9458214 - Dual function fibroblast growth factor 21 proteins (2016-10-04),

9. 9340582 - Bioconjugates of synthetic apelin polypeptides (2016-05-17),

10. 9266935 - Methods of treating metabolic disorders with an FGF21 variant (2016-02-23),

11. 9023791 - Fibroblast growth factor 21 mutations (2015-05-05),

12. 9006400 - Fibroblast growth factor-21-Fc fusion proteins (2015-04-14),

13. 6608038 - Methods and compositions for treatment of diabetes and related conditions via gene therapy (2003-08-19),

Title: Shari Lynn Caplan: Innovator in Pharmaceutical Science

Introduction

Shari Lynn Caplan is a prominent inventor based in Lunenburg, MA (US). She has made significant contributions to the field of pharmaceutical science, holding a total of 13 patents. Her work primarily focuses on advancements related to fibroblast growth factor 21 (FGF21) and its associated disorders.

Latest Patents

Among her latest patents, Shari has developed innovative fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. This invention also includes methods for treating FGF21-associated disorders, particularly metabolic conditions. Additionally, she has created monoclonal antibodies and antigen-binding fragments that bind to human β-klotho, along with pharmaceutical compositions and treatment methods involving these antibodies.

Career Highlights

Shari has worked with notable companies in the pharmaceutical industry, including Novartis AG and Irm LLC. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in her field.

Collaborations

Throughout her career, Shari has collaborated with esteemed colleagues such as Brian R. Boettcher and Douglas S. Daniels. These partnerships have further enhanced her innovative work and expanded her impact in the industry.

Conclusion

Shari Lynn Caplan is a distinguished inventor whose work in pharmaceutical science has led to significant advancements in the treatment of metabolic disorders. Her contributions continue to influence the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.